China’s Xinshidai Gastric Cancer Drug Launch Ends Imports From Japan
This article was originally published in PharmAsia News
Executive Summary
Shandong Xinshidai Pharmaceuticals, a subsidiary of Lunan Pharma Group announced March 18 the launch of Weikangda (tegafur, gimeracil, oteracil). Weikangda is developed in China by Xinshida to treat progressive and inoperable gastric cancer. The drug is marked in Japan by Taiho Pharmaceutical under the name TS-1. Chinese patients previously relied on the higher-cost imported drugs from Japan. (Click here for more - Japanese language
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.